Clinical Trial Update: Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial update for NiCord (umbilical cord blood-derived ex vivo expanded cells) in hematological malignancies, including ALL, AML, and MDS, wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Hematological Malignancies
• Myelodysplastic Syndrome

Drugs mentioned

• NiCord (omidubicel)

Snippet

Sponsor: Gamida Cell ltd | Conditions: Hematological Malignancies, Acute Lymphoblastic Leukemia (ALL) | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-09-21